Sentences with phrase «of placebo patients»

At this point, 72 percent of enzalutamide patients and 63 percent of placebo patients were alive at the trial cutoff date showing a 29 percent overall improvement in survival.

About 69.9 percent of angiotensin II patients achieved the primary endpoint versus 23.4 percent of placebo patients.

Not exact matches

A two - month 2010 study of nearly 300 cancer patients at the Mayo Clinic found that those given 1,000 or 2,000 milligrams of ginseng each day reported feeling more energized compared with those who took a placebo.

In a 564 - person trial, patients whose ovarian cancer recurred (and who had already started treatment with chemotherapy) given Rubraca, part of a new class of cancer drugs called «PARP» inhibitors, lived, on median, for double the amount of time without their disease getting even worse compared with those given a placebo.

The ENDEAVOUR Phase 3 study data monitoring committee recommended dosing be suspended after it found «an imbalance of mortality» in patients who used revusiran as compared to placebo.

It may have to do with Addyi's high pricing (on par with Viagra at $ 26 per pill without an assistance program), its daily intake requirement (unlike Viagra, it adds up to $ 780 per month), its potentially deleterious side effects (low blood pressure and fainting), its restrictions on alcohol consumption (abstinence vs. large quantities not recommended for Viagra patients), a 10 % efficacy rate (whereas Viagra works 50 % of the time compared to a placebo, according to a recent study), and its subtle neurotransmitter - targeting mechanism (contrast that to the obvious hydraulics of Viagra).

The med significantly upped the proportion of patients to achieve a 20 response at week 16 when compared with placebo in patients who hadn't yet received a biologic therapy.

The action is a direct result of its late November announcement that patients with mild to moderate Alzheimer's disease who took solanezumab as part of its EXPEDITION3 trial showed no significant improvements in symptoms compared to placebo.

Patisiran was being evaluated in a late - stage study against a placebo for the treatment of patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy.

In a mid-stage trial, 16 of 37 lung cancer patients given a placebo ahead of standard chemo wound up hospitalized with severely low white blood cell counts.

The patient may be given increasing doses of the food or placebo and is closely monitored throughout this process.

Results: Daily ingestion of wheat - based starch hydrolysates, glucose syrups and maltodextrins, had no deleterious effect on small - bowel mucosal villous architecture or inflammation in coeliac disease patients when compared to the placebo group.

He contributes to other large - scale clinical trials including SAVE (evaluating whether treatment of obstructive sleep apnoea with continuous positive airways pressure can reduce the incidence of serious CV events in patients with established CVD), and CREDENCE, a randomised, double - blind, placebo - controlled trial assessing whether canagliflozin can slow the progression of diabetic nephropathy in patients with type 2 diabetes.

Of the patients seen at 2 weeks postpartum, 4 of 49 (8.2 %) patients who received antibiotics and 14 of 58 (24.1 %) patients who received placebo developed a perineal wound complication (P =.037Of the patients seen at 2 weeks postpartum, 4 of 49 (8.2 %) patients who received antibiotics and 14 of 58 (24.1 %) patients who received placebo developed a perineal wound complication (P =.037of 49 (8.2 %) patients who received antibiotics and 14 of 58 (24.1 %) patients who received placebo developed a perineal wound complication (P =.037of 58 (24.1 %) patients who received placebo developed a perineal wound complication (P =.037).

Each patient was given a single intravenous dose of a second - generation cephalosporin (cefotetan or cefoxitin) or placebo before repair of third - or fourth - degree perineal tears.

The government is reluctant to address the appropriateness and ethics of prescribing placebos to patients, which usually relies on some degree of patient deception, the report concludes.

I'll give real life examples of nocebo, from the man who almost put himself in a coma after «overdosing» on placebo anti-depressants, to the patient mis - diagnosed with liver cancer who died tumour - free within the three months he was told he had left to live.

The phase III study was conducted among 366 patients with TSC and epilepsy from 25 countries who were randomly assigned to either a placebo, a low dose of everolimus or a higher dose.

Researchers report that the only substantial difference in safety outcomes between the placebo and bococizumab groups was injection site reactions, which is also the result of the immunologic response in some patients.

Two other multi-national trials randomized 27,438 patients to either bococizumab or placebo and were designed to evaluate the impact of the drug on cardiovascular outcomes, including nonfatal heart attack and stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death.

Hep C patients being treated for opioid addiction achieved high rates of sustained virologic response after 12 weeks of therapy with elbasvir - grazoprevir compared to those taking placebo for 12 weeks before beginning the drug treatment.

A «Perspectives» article in the July 2 issue of The New England Journal of Medicine (NEJM) proposes that placebos be more broadly considered as valuable components of medical care and important tools in relieving patients» symptoms.

The field is also expanding into patient - centered outcomes research, so not just comparing drug A with a placebo, but drug A versus drug B.» In spite of the uncertainties, she says, «It's an exciting time because we have a lot to learn.»

Patients were randomized to receive 48 - hour infusions of placebo or serelaxin (30µg / kg per day) within 16 hours from presentation.

At baseline, study patients had an average Clinician - Administered PTSD Scale (CAPS) score of 79, but after MDMA - assisted therapy, CAPS scores dropped to 23.4 in the 13 - person MDMA group, whereas an eight - person placebo group averaged a score of 60.

The authors define the placebo effect as relief of symptoms that arise from patients» overall medical encounters including responses to medical symbols (such as medical diplomas prominently displayed on the wall or words on a medication bottle) and, importantly, patient - physician interactions.

Patients were randomised into eight treatment groups: a single dose regimen of 200, 300 or 500 mg inclisiran, or placebo; or a two dose regimen of 100, 200 or 300 mg inclisiran, or placebo, at days one and 90.

«A significant body of research has resulted in a shift from thinking of placebos as just «dummy» treatments to recognizing that placebo effects encompass numerous aspects of the health care experience and are central to medicine and patient care,» said the article's coauthor Ted Kaptchuk, Director of the Program in Placebo Studies at Beth Israel Deaconess Medical Center (BIDMC) and Professor of Medicine at Harvard Medical placebo effects encompass numerous aspects of the health care experience and are central to medicine and patient care,» said the article's coauthor Ted Kaptchuk, Director of the Program in Placebo Studies at Beth Israel Deaconess Medical Center (BIDMC) and Professor of Medicine at Harvard Medical Placebo Studies at Beth Israel Deaconess Medical Center (BIDMC) and Professor of Medicine at Harvard Medical School.

According to the authors, placebo effects can dramatically enhance the effectiveness of pharmaceutical therapies, as shown in studies of patients with irritable bowel disease and episodic migraine.

Scientists showed placebo pill ingestion is associated with a strong analgesia effect, with more than half of the patients reporting significant pain relief.

None of the Actimel patients developed the more dangerous C. difficile diarrhea, compared with 17 percent of the placebo group.

This was the case in the new study, published in the journal Archives of General Psychiatry — patients with major depressive disorder who were given a placebo saw their symptoms improve about three quarters as much as those given paroxetine, an antidepressant also known as Paxil.

But those results didn't hold up in a larger group of 139 patients randomized to take opioids or placebo, nor did they appear in a different pain test that applied a gradually heated probe to the forearm.

Fred Hayden of the University of Virginia at Charlottesville says both Tamiflu and placebo patients in the randomised controlled trials were also on paracetamol (acetaminophen), so the two were indeed compared.

Patients spent nine nights and twelve sessions of neurofeedback and twelve sessions of placebo - feedback training (sham) in researchers» laboratory.

As this study focuses on neurofeedback effects on EEG, sleep and quality of life in insomnia patients, insomnia patients underwent this procedure before and after real as well as placebo neurofeedback training.

At the end of the study, 206 out of 1722 patients on spironolactone (12 percent) had been hospitalized for heart failure, compared to 245 of 1723 patients (14 percent) given placebo.

Only 12 percent of the patients who received Actimel developed diarrhea compared with 34 percent of the patients who got the placebo.

«The greater the improvement in patients treated with placebo in clinical trials, the more difficult it can be to demonstrate the beneficial effects of pain - relieving medications,» said Robert H. Dworkin, Professor of Anesthesiology, Neurology, and Psychiatry at the University of Rochester School of Medicine and Dentistry.

Experts have long known that the placebo effect explains much of the mood lift patients report after going on antidepressants.

Some of the best support for this contention came in 2012, when researchers at Memorial Sloan Kettering Cancer Center and their colleagues published a meta - analysis of 29 studies involving nearly 18,000 patients, which found that traditional acupuncture produced a somewhat greater reduction in pain than placebo or sham acupuncture.

She had learned that fibromyalgia patients struggled to access certain opioid - related brain regions, including the ACC — the center of emotion, reward and pain that Petrovic had found played a role in placebos.

The strangest part of the patient's grim plan: His pills were placebos.

Jensen says many doctors cripple their chances of leveraging the placebo effect by acting disinterested or lacking confidence with patients.

After four weeks of hospital treatment, the subjects taking the drug reported fewer spontaneous and stress - induced alcohol cravings than patients given a placebo did.

About 11 per cent of patients were not able to tolerate medical cannabinoids, versus three per cent of those taking placebo.

In a recent trial of 225 patients, completed in September 2016, participants who took the drug (along with their other epilepsy medications) reduced their nonstop seizures by 42 percent, compared with 17 percent for those taking a placebo.

In patients with muscle spasticity, 25 per cent of those taking a placebo saw a moderate improvement compared to 35 per cent on medical cannabis.

While 35 per cent of the patients who had not received any treatment reported an improvement, 59 per cent of the placebo group felt better.

Only in patients with moderate or severe knee pain at the outset did the supplements show a significant advantage over the placebo, with almost 80 percent of that group reporting a significant improvement, compared with 54.3 percent who took the inert pills.